全凭随机对照试验不可能写好临床指南
摘要
美国心肺血液研究院（NHLBI）于2008年同步启动成人高血压管理指南（以下简称美国高血压指南）、胆固醇治疗指南等五部新版心血管疾病预防指南的撰写工作，并且信心满满地宣布，这些新指南的推荐内容将基于循证医学证据，其中高血压指南和胆固醇治疗指南将完全基于来自随机对照临床试验（randomized controlled trial，RCT）的证据。然而，这一要求导致五部新指南的撰写极度困难，拖沓到2013年才陆续完稿和发表[2-6]，而且其推荐内容并非完全基于RCT。例如，美国高血压指南共有9条正式推荐和1条附加推荐，10条推荐中有5.5条为专家共识[6]。这一事实表明，全凭RCT不可能写好临床指南。
出处
《中国处方药》
2014年第3期8-10,共3页
Journal of China Prescription Drug
参考文献23
-
1施仲伟.美国2013版四项心血管疾病预防指南要点全览[J].中国处方药,2014,12(1):1-3. 被引量：1
-
2Stone NJ, Robinson J, LichtensteinAH, et al. 2013 ACC/AHA guideline onthe treatment of blood cholesterol to reduceatherosclerotic cardiovascular risk in adults: areport of the American College of Cardiology/American Heart Association Task Force onPractice Guidelines. Circulation, publishedonline November 12, 2013.
-
3Goff DC Jr, Lloyd-Jones DM, BennettG, et al. 2013 ACC/AHA guideline on theassessment of cardiovascular risk: a report of theAmerican College of Cardiology/American HeartAssociation Task Force on Practice Guidelines.Circulation, published online November 12,2013.
-
4Jensen MD, Ryan DH, Apovian CM,et al. 2013 AHA/ACC/TOS guideline for themanagement of overweight and obesity in adults:a report of the American College of Cardiology/American Heart Association Task Force onPractice Guidelines and The Obesity Society.Circulation, published online November 12, 2013.
-
5Eckel RH, Jakicic JM, Ard JD, etal. 2013 AHA/ACC guideline on lifestylemanagement to reduce cardiovascular risk: areport of the American College of CardiologyAmerican/Heart Association Task Force onPractice Guidelines. Circulation, publishedonline November 12, 2013.
-
6James PA, Oparil S, Carter BL, etal. 2014 evidence-based guideline for themanagement of high blood pressure in adults:report from the panel members appointed tothe Eighth Joint National Committee( JNC 8).JAMA, 2014, 311(5):507-520.
-
7Califf RM Zarin DA, Kramer, JM, etal. Characteristics of clinical trials registered inClinicalTrials.gov, 2007-2010. JAMA, 2012,307(17):1838-1847.
-
8Ross JS, Mulvey GK, Hines EM,et al. Trial publication after registration inClinicalTrials.Gov: a cross-sectional analysis.PLoS Med, 2009, 6(9):e1000144.
-
9CIBIS-II Investigators and Committees.The Cardiac Insufficiency Bisoprolol Study II(CIBIS II): a randomized trial. Lancet, 1999,353(9146):9-13.
-
10MERIT-HF Study Group. Effectof metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomized InterventionTrial in Congestive Heart Failure( MERIT-HF).Lancet, 1999, 353(9169):2001-2007.
二级参考文献23
-
1[1]Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low - dose beta - blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol, 1985; 55(4): 471 ～ 475
-
2[2]Waagestein F, Bristow MR, Swedberg K, et al. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet, 1993; 342(8885):1441～1446
-
3[3]MERIT - HF Study Group. Effect of metoprolol CR/ XL in chronic heart failure:Metoprolol CR/ XL Randomized Intervention Trial in Congestive Heart Failure (MERIT- HF) . Lancet, 1999; 353(9169): 2001 ～ 2007
-
4[4]Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled - release metoprolol on total mortality, hospitalizations, and well - being in patients with heart failure.The Metoprolol CR/ XL Randomized Intervention Trial in Congestive Heart Failure (MERIT- HF). JAMA, 2000; 283( 10): 1295 ～ 1302
-
5[5]CIBIS Investigators and Committees. A randomized trim of β - blockade in heart failure:the cardiac insufficiency bisoprolol study (CIBIS). Circulation, 1994; 90(4): 1765 ～1773
-
6[6]CIBIS - Ⅱ Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study Ⅱ(CIBIS Ⅱ): a randomized trial. Lancet, 1999; 353(9146): 9～ 13
-
7[7]Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation, 1996; 94(11): 2800 ～ 2806
-
8[8]Packer M, Colucci WS, Sackner - Bernstein JD, et al. Double - blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Circulation, 1996; 94(11): 2793 ～ 2799
-
9[9]Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose - related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation, 1996; 94(11): 2807 ～ 2816
-
10[10]Teerlink JR, Massie BM. Beta - adrenergic blocker mortMity trials in congestive heart failure. Am J Cardle, 1999; 84(9A): 94R ～ 102R
共引文献3
-
1许恒忠,李金英,刘金英.β受体阻滞剂在心力衰竭治疗中的应用[J].中南药学,2003,1(3):171-173. 被引量：1
-
2董蔚,任艺虹,智光,徐勇,石亚君,李乐燕,卢喜烈,盖鲁粤.三种β受体阻滞剂在慢性心力衰竭治疗中对糖脂代谢影响的比较[J].中国综合临床,2007,23(2):100-102. 被引量：2
-
3傅涛,李洁,郭晋爱,荆忱,陈杰,陈宏.富马酸比索洛尔治疗缺血性心肌病室性心律失常和心力衰竭的疗效和安全性评价[J].北京医学,2010,32(11):906-909. 被引量：5
-
1扬帆（编译）.激素治疗晚期急性呼吸窘迫综合征患者需谨慎[J].世界急危重病医学杂志,2006,3(3):1344-1344.
-
2结核病遗传学研究进展及新方向[J].河南医学研究,2006,15(2):162-162.
-
3AHA/NHLBI肯定了代谢综合征的重要性[J].世界核心医学期刊文摘（心脏病学分册）,2005,0(11):14-14.
-
4吴天明,张晶.SREBP1c在胰岛素相关代谢性疾病中的作用及机制[J].河北医科大学学报,2013,34(3):361-364.
-
5沈晓旭.夏天，降压药能停吗[J].大众健康,2015,0(7):50-50.
-
6刘力生.美国高血压预防、检测、评估与治疗联合委员会第8次报告解读及给我们的启示[J].中华高血压杂志,2014,22(2):116-118. 被引量：4
-
7李蕾.NHLBI发表输血相关性急性肺损伤定义[J].世界急危重病医学杂志,2005,2(3):711-711.
-
8本刊编辑部.新的临床试验结果对于2001年美国成人胆固醇治疗指南(ATPⅢ)的修订[J].中华糖尿病杂志（1006-6187）,2004,12(4):272-272.
-
9顾平,陈岷,李晋奇,童荣生.替米沙坦对比氨氯地平治疗高血压合并糖尿病的疗效和安全性的Meta分析[J].中国生化药物杂志,2016,36(4):203-206. 被引量：40
-
10彭伊,叶远征,祖丽菲娅·木沙,范平.β受体阻滞剂治疗高血压的疗效荟萃分析[J].中国基层医药,2014,21(16):2438-2441. 被引量：5
